Mpox (formerly Monkeypox) Vaccination Information

One vaccine, JYNNEOSTM (also known as Imvamune or Imvanex), is currently licensed in the United States to prevent Mpox. JYNNEOS and another vaccine, ACAM2000, are licensed in the United States to prevent smallpox. Both can be used before and after exposure to Mpox in an outbreak setting. However, ACAM2000 carries a higher potential for more serious side effects and adverse events than JYNNEOS and may not be an appropriate option for all patients. Contact the local public health authority to connect patients with Mpox vaccination.

    Health Care Providers

    Most clinicians in the United States are not advised to receive Orthopoxvirus pre-exposure prophylaxis (PrEP). Reference CDC’s guidance on Infection Prevention and Control of Mpox in Healthcare Settings for the most up-to-date information regarding PPE and other infection prevention strategies.

      Post-Exposure Prophylaxis

      Vaccination after exposure to a person infected with Mpox virus may help prevent disease or reduce severity of symptoms. Post-exposure prophylaxis (PEP) is recommended for individuals who have had a high degree of exposure. Brief interactions and those conducted using appropriate PPE are not considered high risk and generally do not warrant PEP. For more information, visit Monitoring People Who Have Been Exposed | Mpox | Poxvirus | CDC

      • People who qualify for PEP should be vaccinated as soon as possible after the exposure. Timely reporting of suspected cases of Mpox to public health authorities helps ensure close contacts can receive PEP.

      Outbreak Response Mpox Vaccine Post-Exposure Prophylaxis (PEP++)

      People with certain risk factors are more likely to have been recently exposed to Mpox. The PEP++ approach aims to reach these people for post-exposure prophylaxis, even if they do not have documented exposure to someone with confirmed Mpox. Nevada’s current vaccine allocation is limited; highest priority for vaccine administration is PEP for those that have a known exposure to someone with Mpox.

        Pre-Exposure Prophylaxis

        Pre-exposure prophylaxis (PrEP) is recommended for certain laboratory personnel who perform Orthopoxvirus testing. At this time, most clinicians and laboratorians in the United States are not advised to receive Orthopoxvirus PrEP. PrEP is not currently available for members of the public.

        Currently, the CDC is not recommending routine immunization (or pre-exposure prophylaxis, PrEP) against Mpox for the general public. PrEP can be provided for individuals at increased risk for exposure to Mpox, including members of specific populations that are being highly impacted. PrEP is recommended for certain laboratory personnel who perform orthopoxvirus testing. At this time, most clinicians and laboratorians in the United States are not advised to receive orthopoxvirus PrEP. For more information about the national vaccine strategy, visit: Vaccination | Mpox | Poxvirus | CDC.

          Emergency Use Authorization of JYNNEOS

          On August 9, 2022, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) — following the public health emergency (PHE) declared by the U.S. Department of Health and Human Services — for the JYNNEOS vaccine to allow health care providers to use the vaccine by intradermal injection for individuals 18 years of age and older who are determined to be at high risk for Mpox infection. The EUA also allows for use of the vaccine in individuals younger than 18 years of age determined to be at high risk of Mpox infection; in these individuals JYNNEOS is administered by subcutaneous injection.

          The standard regimen for JYNNEOS involves an administration of .5 mL subcutaneous (subcut) injection (the entire vial). This standard regimen is the FDA-approved dosing regimen. As of August 9, 2022, this standard regimen has been authorized for people aged <18 years under an Emergency Use Authorization. (CDC- JYNNEOS Vaccine)

          In the context of the current national PHE, an alternative regimen may be used for people age ≥18 years under an Emergency Use Authorization beginning August 9, 2022. The authorized alternative regimen is an intradermal (ID) route of administration with an injection volume of 0.1mL (1/5th of the vial). This approach could increase the number of available JYNNEOS vaccine doses by up to five-fold. (CDC-JYNNEOS vaccine)

            CPT Coding Guidance

            The Editorial Panel approved one code (87593) to report the laboratory diagnostic testing for the Orthopoxvirus and two new vaccine product codes (90611, 90622) for the smallpox and Mpox combined vaccine (JYNNEOS) and the traditional smallpox vaccine (ACAM2000), respectively. These codes are effective immediately for use in reporting the laboratory test for the Orthopoxvirus and vaccine administration utilizing these vaccine products. (CPT Assistant Guide)

              Additional Resources

              Mpox Vaccine Eligibility Criteria

              Persons currently eligible to receive the vaccine include the following:

              • Those who had close physical contact within the past 14 days with someone known or suspected of having Mpox.
                • This includes:
                  • Those who know or suspect their sexual partner(s) of having Mpox.
                  • Those who live in the same household as someone they know or suspect of having Mpox. 
              • Those who have been informed by their local health department they are a close contact of someone with Mpox.
              • Gay, bisexual, or other men who have sex with men, and/or transgender, gender non-conforming, or gender non-binary who had multiple or anonymous sex partners in the last 14 days, especially at a venue, event, or within a social group where a person with a known or suspected case of Mpox was present. 
              Individuals who have had Mpox are not eligible for the vaccine. Vaccine clients will be assessed prior to receiving the vaccine to ensure they meet the eligibility requirements. If you meet the above criteria and would like to schedule an appointment to receive Mpox vaccine, please check with your local health department/community health nursing clinic for the community in which you live:


              Clark County
              Southern Nevada Health District
              Phone: 702-759-INFO(4636)

              Carson City and Douglas Counties
              Carson City Health and Human Services

              Washoe County
              Washoe County Health District
              Phone: 775-328-2447

              Rural Community Health Nursing Clinics
              Churchill County (Fallon)
              Phone: 775-423-4434

              Humboldt County (Winnemucca)
              Phone: 775-623-6575

              Lincoln County (Panaca)
              Phone: 775-962-8086

              Lyon County (Dayton)
              Phone: 775-246-6211

              Lyon County (Fernley)
              Phone: 775-575-3363

              Lyon County (Yerington)
              Phone: 775-463-6539

              Mineral County (Hawthorne)
              Phone: 775-945-3657

              Nye County (Pahrump)
              Phone: 775-751-7070

              Nye County (Tonopah)
              Phone: 775-482-6659

              Pershing County (Lovelock)
              Phone: 775-273-2041

              White Pine County (Ely)